Comparison of the CEDIA® and MEIA® assays for measurement of tacrolimus in organ transplant recipients

Shu Ling Liang, Autumn Breaud, Willard Dunn, William Clarke

Research output: Contribution to journalArticle

Abstract

Objectives: Tacrolimus is widely used in organ transplantation. We evaluated 2 immunoassays, CEDIA® and MEIA®, for the measurement of whole blood tacrolimus concentrations. Methods: For each assay the following were evaluated: total precision, limit of detection (analytical sensitivity), limit of quantitation (functional sensitivity), linearity, and accuracy. Patient correlation studies were performed, comparing each assay with liquid chromatography-tandem mass spectrometry (LC-MS/MS). Results: Total precision for MEIA, corresponding to mean concentrations of 6.8 and 22.5 ng/ml, was 17.4 and 11.9%, respectively. The limit of detection was 0.9 ng/ml, and the limit of quantitation was 4.7 ng/ml. Total precision for CEDIA, corresponding to mean concentrations of 5.3 and 19.9 ng/ml, was 20.6 and 6.3%, respectively. The limit of detection was 0.8 ng/ml, with a limit of quantitation of 4.9 ng/ml. Analysis of proficiency material demonstrated acceptable performance for both assays. In addition, both assays were acceptably linear over their respective reportable ranges. Analysis of patient correlation data using Passing-Bablok analysis and Bland-Altman plots demonstrated a positive average bias for both assays versus LC-MS/MS results. Conclusion: Based on our evaluation, both assays demonstrated acceptable performance for use in clinical monitoring of tacrolimus.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalClinica Chimica Acta
Volume396
Issue number1-2
DOIs
StatePublished - Oct 2008

Fingerprint

Transplants
Tacrolimus
Limit of Detection
Assays
Organ Transplantation
Tandem Mass Spectrometry
Immunoassay
Liquid Chromatography
Transplantation (surgical)
Liquid chromatography
Mass spectrometry
Transplant Recipients
Blood
Monitoring

Keywords

  • Assay evaluation
  • Method comparison
  • Organ transplant
  • Tacrolimus

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Comparison of the CEDIA® and MEIA® assays for measurement of tacrolimus in organ transplant recipients. / Liang, Shu Ling; Breaud, Autumn; Dunn, Willard; Clarke, William.

In: Clinica Chimica Acta, Vol. 396, No. 1-2, 10.2008, p. 1-6.

Research output: Contribution to journalArticle

@article{127e6aea42974928986bdf26dc94f357,
title = "Comparison of the CEDIA{\circledR} and MEIA{\circledR} assays for measurement of tacrolimus in organ transplant recipients",
abstract = "Objectives: Tacrolimus is widely used in organ transplantation. We evaluated 2 immunoassays, CEDIA{\circledR} and MEIA{\circledR}, for the measurement of whole blood tacrolimus concentrations. Methods: For each assay the following were evaluated: total precision, limit of detection (analytical sensitivity), limit of quantitation (functional sensitivity), linearity, and accuracy. Patient correlation studies were performed, comparing each assay with liquid chromatography-tandem mass spectrometry (LC-MS/MS). Results: Total precision for MEIA, corresponding to mean concentrations of 6.8 and 22.5 ng/ml, was 17.4 and 11.9{\%}, respectively. The limit of detection was 0.9 ng/ml, and the limit of quantitation was 4.7 ng/ml. Total precision for CEDIA, corresponding to mean concentrations of 5.3 and 19.9 ng/ml, was 20.6 and 6.3{\%}, respectively. The limit of detection was 0.8 ng/ml, with a limit of quantitation of 4.9 ng/ml. Analysis of proficiency material demonstrated acceptable performance for both assays. In addition, both assays were acceptably linear over their respective reportable ranges. Analysis of patient correlation data using Passing-Bablok analysis and Bland-Altman plots demonstrated a positive average bias for both assays versus LC-MS/MS results. Conclusion: Based on our evaluation, both assays demonstrated acceptable performance for use in clinical monitoring of tacrolimus.",
keywords = "Assay evaluation, Method comparison, Organ transplant, Tacrolimus",
author = "Liang, {Shu Ling} and Autumn Breaud and Willard Dunn and William Clarke",
year = "2008",
month = "10",
doi = "10.1016/j.cca.2008.06.007",
language = "English (US)",
volume = "396",
pages = "1--6",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Comparison of the CEDIA® and MEIA® assays for measurement of tacrolimus in organ transplant recipients

AU - Liang, Shu Ling

AU - Breaud, Autumn

AU - Dunn, Willard

AU - Clarke, William

PY - 2008/10

Y1 - 2008/10

N2 - Objectives: Tacrolimus is widely used in organ transplantation. We evaluated 2 immunoassays, CEDIA® and MEIA®, for the measurement of whole blood tacrolimus concentrations. Methods: For each assay the following were evaluated: total precision, limit of detection (analytical sensitivity), limit of quantitation (functional sensitivity), linearity, and accuracy. Patient correlation studies were performed, comparing each assay with liquid chromatography-tandem mass spectrometry (LC-MS/MS). Results: Total precision for MEIA, corresponding to mean concentrations of 6.8 and 22.5 ng/ml, was 17.4 and 11.9%, respectively. The limit of detection was 0.9 ng/ml, and the limit of quantitation was 4.7 ng/ml. Total precision for CEDIA, corresponding to mean concentrations of 5.3 and 19.9 ng/ml, was 20.6 and 6.3%, respectively. The limit of detection was 0.8 ng/ml, with a limit of quantitation of 4.9 ng/ml. Analysis of proficiency material demonstrated acceptable performance for both assays. In addition, both assays were acceptably linear over their respective reportable ranges. Analysis of patient correlation data using Passing-Bablok analysis and Bland-Altman plots demonstrated a positive average bias for both assays versus LC-MS/MS results. Conclusion: Based on our evaluation, both assays demonstrated acceptable performance for use in clinical monitoring of tacrolimus.

AB - Objectives: Tacrolimus is widely used in organ transplantation. We evaluated 2 immunoassays, CEDIA® and MEIA®, for the measurement of whole blood tacrolimus concentrations. Methods: For each assay the following were evaluated: total precision, limit of detection (analytical sensitivity), limit of quantitation (functional sensitivity), linearity, and accuracy. Patient correlation studies were performed, comparing each assay with liquid chromatography-tandem mass spectrometry (LC-MS/MS). Results: Total precision for MEIA, corresponding to mean concentrations of 6.8 and 22.5 ng/ml, was 17.4 and 11.9%, respectively. The limit of detection was 0.9 ng/ml, and the limit of quantitation was 4.7 ng/ml. Total precision for CEDIA, corresponding to mean concentrations of 5.3 and 19.9 ng/ml, was 20.6 and 6.3%, respectively. The limit of detection was 0.8 ng/ml, with a limit of quantitation of 4.9 ng/ml. Analysis of proficiency material demonstrated acceptable performance for both assays. In addition, both assays were acceptably linear over their respective reportable ranges. Analysis of patient correlation data using Passing-Bablok analysis and Bland-Altman plots demonstrated a positive average bias for both assays versus LC-MS/MS results. Conclusion: Based on our evaluation, both assays demonstrated acceptable performance for use in clinical monitoring of tacrolimus.

KW - Assay evaluation

KW - Method comparison

KW - Organ transplant

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=50049126893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50049126893&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2008.06.007

DO - 10.1016/j.cca.2008.06.007

M3 - Article

C2 - 18606158

AN - SCOPUS:50049126893

VL - 396

SP - 1

EP - 6

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 1-2

ER -